{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:11:53Z","timestamp":1779275513846,"version":"3.51.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The success of tyrosine kinase inhibtors in the neoadjuvant and adjuvant setting provides a rationale for exploring selpercatinib in the perioperative setting to improve patient outcomes in early-stage lung cancer. However, selpercatinib is currently only approved as first-line treatment for advanced rearrangement during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), limiting its use and potential benefit for earlier stage patients. Hence, this case report explores selpercatinib\u2019s potential use in early-stage disease to address this treatment gap and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report the case of a 75-year-old female with no history of smoking who was referred to our institute with a chest computed tomography scan revealing a mass in the right lower lung lobe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was diagnosed with RET fusion-positive lung adenocarcinoma based on findings from radiologic findings from computed tomography (CT) and positron emission tomography-CT scans, histopathological examination, and molecular profiling through next-generation sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was treated with 4 cycles of carboplatin and pemetrexed. A follow-up CT scan revealed the progression of the mediastinal lymph node, leading to the decision to initiate selpercatinib treatment. Due to a major size reduction of the primary lesion and the absence of tumor cells in the lymph nodes, the patient underwent curative lobectomy and lymphadenectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Preoperative selpercatinib induced tumor regression, enabling surgical resection. Histopathological examination of the resected tumor revealed a major pathological response to preoperative selpercatinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case highlights the potential of selpercatinib in the perioperative setting, suggesting that it induces tumor regression and enabling of curative surgery in early-stage RET fusion-positive NSCLC. Our findings support the further investigation of selpercatinib in early stages and provide a rationale for future treatment strategies of early-stage RET fusion-positive NSCLC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045554","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:02:11Z","timestamp":1763571731000},"page":"e45554","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-6377","authenticated-orcid":false,"given":"Kristina","family":"Breitenecker","sequence":"first","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fabikan","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Weinlinger","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Krenbek","sequence":"additional","affiliation":[{"name":"Department of Pathology, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klikovits","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute for Clinical and Translational Thoracic Surgery Research, Klinik Floridsdorf, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4149-4890","authenticated-orcid":false,"given":"Stefan","family":"Watzka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria"},{"name":"Karl Landsteiner Institute for Clinical and Translational Thoracic Surgery Research, Klinik Floridsdorf, Vienna, Austria"},{"name":"Paracelsus Medical University, Salzburg, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arschang","family":"Valipour","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria"},{"name":"Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-2450","authenticated-orcid":false,"given":"Maximilian Johannes","family":"Hochmair","sequence":"additional","affiliation":[{"name":"Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria"},{"name":"Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260520","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer.","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20260520","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20260520","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"R4-20260520","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET Fusion-Positive NSCLC.","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"R5-20260520","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC.","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"R6-20260520","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer.","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"R7-20260520","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cllc.2021.02.014","article-title":"Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO Trial.","volume":"22","author":"Leonetti","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"R8-20260520","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"key":"R9-20260520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s002920050201","article-title":"[Regression grading of neoadjuvant non-small-cell lung carcinoma treatment].","volume":"18","author":"Junker","year":"1997","journal-title":"Pathologe"},{"key":"R10-20260520","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"R11-20260520","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy.","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"R12-20260520","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.2217\/fon-2022-0656","article-title":"LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.","volume":"18","author":"Tsuboi","year":"2022","journal-title":"Future Oncol"},{"key":"R13-20260520","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer.","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"R14-20260520","doi-asserted-by":"crossref","first-page":"TPS8594","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8594","article-title":"LIBRETTO-001 cohort 7: a single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA <i>RET<\/i> fusion-positive NSCLC.","volume":"40","author":"Rajaram","year":"2022","journal-title":"J Clin Oncol"},{"key":"R15-20260520","doi-asserted-by":"crossref","first-page":"1178313","DOI":"10.3389\/fonc.2023.1178313","article-title":"Case report: complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.","volume":"13","author":"Goldman","year":"2023","journal-title":"Front Oncol"},{"key":"R16-20260520","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/hed.26527","article-title":"Neoadjuvant selpercatinib for advanced medullary thyroid cancer.","volume":"43","author":"Jozaghi","year":"2021","journal-title":"Head Neck"},{"key":"R17-20260520","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/thy.2024.0090","article-title":"Neoadjuvant treatment of locally advanced thyroid cancer: a preliminary latin American experience.","volume":"34","author":"Pitoia","year":"2024","journal-title":"Thyroid"},{"key":"R18-20260520","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1007\/s00432-022-04496-y","article-title":"Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.","volume":"149","author":"Schrenk","year":"2023","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:03:17Z","timestamp":1779274997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":18,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045554","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}